In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Bruker, with a price target of $60.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Ryskin has given his Buy rating due to a combination of factors including Bruker’s strong confidence in their 2026 financial framework, which anticipates flat to low single-digit organic revenue growth, a 300 basis points margin expansion, and double-digit EPS growth. The company expects headwinds in key end markets to diminish and has observed encouraging trends in recent quarters, particularly in the pharmaceutical sector where R&D activity is picking up.
Additionally, Bruker’s margin improvement initiatives, which include significant cost reductions, are on track to achieve the higher end of their targets, supporting a positive outlook for operating margins. While there are some uncertainties in the US Academic and Government sectors, these account for a small portion of Bruker’s total sales, and the company remains optimistic about its overall growth trajectory. This confidence in future performance and strategic positioning in the market underpins Ryskin’s Buy recommendation.
In another report released today, Barclays also maintained a Buy rating on the stock with a $55.00 price target.